TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04359199

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Routine radiation dosing (approximately 70 Gy in 35 fractions over 6.5 weeks) to the head and neck for the treatment of head and neck cancer

Intervention type: DRUG
Intervention: Cetuximab
Description: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of head and neck cancer

Intervention type: DRUG
Intervention: Chemotherapy
Description: Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer

Intervention type: DRUG
Intervention: Immunotherapy
Description: Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.~Opdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.~Imfinzi or Durvalumab is an anti-cancer (antineoplastic) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody.
Study: NCT03486015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: 2 ml of sterile water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% glucose
Description: 2 ml of 30% glucose
Study: NCT03444493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercises were basically performed in 3 phases in this study. In the first phase; effectively and correctly contraction of TrA and multifidus muscles and how the patients adapted to daily life activities was taught. In the second phase; was aimed that the protection of stabilization by counteracting more muscle activation, in the third phase neutral position along with the activities required high level control.
Study: NCT02995317

Intervention type: OTHER
Intervention: Number of falls based on an one year follow-up
Study: NCT02532608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute sleep deprivation
Description: Participants will stay awake for 36 hours
Study: NCT03741335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
Study: NCT00295919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide lipid matrix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT03713125

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading Tutoring
Description: 20 hours of 1:1 reading tutoring intervention over 6 weeks
Study: NCT03323034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT03568942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
Study: NCT02203812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Arm
Description: Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
Study: NCT04147442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid with fine-tuned and standard programs
Description: A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
Study: NCT02084771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Saline
Description: Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Salt and Water
Description: Oral salt capsules and water, based on patient weight
Study: NCT03868059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1021
Description: LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
Study: NCT00040326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anteromesial temporal resection
Description: surgical treatment for epilepsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiepileptic drugs
Description: pharmacotherapy
Study: NCT00344968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide
Description: 0.5 mg fluocinolone acetonide intravitreal insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.2 mg fluocinolone acetonide intravitreal insert

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard of care laser photocoagulation
Description: Laser photocoagulation
Study: NCT03251443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
Study: NCT02649127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: imaginal therapy
Description: imaginal exercise of Prolonged Exposure therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: imaginal therapy
Description: imaginal exercise of Prolonged Exposure therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity \[i. e., \>60% of oxygen uptake reserve (VO2R)\], and a time of 20-25 minutes each bout of training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity \[i. e., \>60% of oxygen uptake reserve (VO2R)\], and a time of 20-25 minutes each bout of training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-care
Description: meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
Study: NCT01422876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose FDC
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773 high dose
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose FDC placebo
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose FDC placebo
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose FDC placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose FDC placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose FDC placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose FDC placebo
Description: once daily
Study: NCT00938483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutramigen Lipil (Infant formula)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutramigen Lipil (Infant formula)
Study: NCT00358527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray (MFNS)
Description: MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
Study: NCT01422876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose BI 10773 placebo
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose FDC
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose FDC placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773 low dose
Description: low dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose BI 10773 placebo
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose BI 10773 placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose FDC placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin placebo
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 low dose placebo
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose BI 10773 placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose BI 10773 placebo
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 low dose placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose BI 10773 placebo
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin placebo
Description: once daily
Study: NCT03306875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
Study: NCT03143075

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day
Description: Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day
Description: Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
Study: NCT03618420

Intervention type: DRUG
Group type: OTHER
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Study: NCT02637518

Intervention type: OTHER
Intervention: Assessment of frailty tools in elderly people
Description: Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)

Intervention type: OTHER
Intervention: Assessment of frailty tools in elderly people
Description: Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)

Intervention type: OTHER
Intervention: Assessment of frailty tools in elderly people
Description: Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)

Intervention type: OTHER
Intervention: Assessment of frailty tools in elderly people
Description: Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
Study: NCT03618420

Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol Inj 300 mg/mL
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Study: NCT00358527

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
Study: NCT03817619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zepatier whole tablet
Description: Single-dose ELB/GZR as a whole tablet in a fasted state.
Study: NCT02637518

Intervention type: OTHER
Intervention: Assessment of frailty tools in elderly people
Description: Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
Study: NCT04353427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Seven Pathways to Healing, Health and Wellness curriculum
Description: The curriculum seeks to increase civic engagement by fostering a sense of community and a sense of social and personal responsibility in community. There will be 7 monthly session that will be approximately 1 hour in duration. Session topics include:~1. Education and Information (including mental health awareness, and a one-day certificate program in Mental Health First Aid)~2. Connection with Others~3. The Body as Temple~4. Emotional Healing~5. The Nature of Mind~6. Life Assessment~7. The Nature of Spirit
Study: NCT00641004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide and Esomeprazole
Description: 1. Rebamipide 100mg TID for 12 weeks~2. Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks
Study: NCT01857011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Iron sucrose
Description: Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
Study: NCT00641004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide and Esomeprazole
Description: 1. Rebamipide 100mg TID for 12 weeks~2. Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks
Study: NCT00882232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linked hyaluronan gel
Description: Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy.
Study: NCT02817126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted resection
Description: Arm I: Robot-assisted resection using da vinci system.
Study: NCT01857011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
Study: NCT00235300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin [Anti-thymocyte Globulin (rabbit)]
Description: 1.5 mg/kg per day, for a maximum of 5 doses
Study: NCT02817126

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic resection
Description: Arm II: Traditional laparoscopic resection.
Study: NCT02195570

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quit Smoking Now (QSN)
Description: The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quit Smoking Now (QSN)
Description: The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prize-based Contingency Management (CM)
Description: Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
Study: NCT01308086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles
Study: NCT00235300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect (basliximab)
Description: 20 mg per day on 2 days
Study: NCT03480243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil (UCB0942)
Description: * Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: * Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use
Study: NCT01991756

Intervention type: DEVICE
Intervention: Altura Endograft System
Description: Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
Study: NCT01308086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
Study: NCT03791970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orchid 035 DCB Catheter
Description: Stents placement for femoropopliteal arterial occlusions following with Orchid 035 DCB Catheter for post-dilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA Catheter
Description: Stents placement for femoropopliteal arterial occlusions following with POBA for post-dilation
Study: NCT03335410

Intervention type: OTHER
Intervention: Non- interventional
Description: Non- interventional
Study: NCT00585117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-imaging with CuATSM
Description: imaging with CuATSM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Imaging with CuATSM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET CuATSM
Description: Imaging with CuATSM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: imaging with CuATSM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET imaging with CuATSM
Description: Imaging with CuATSM
Study: NCT04960137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: button plates fixation system
Description: The button plates fixation system consists of fixing plate, prefabricated mix, button and fuse. In the process of use, the fuse plays the role of guiding the fixed plate through, pulling the button and shortening the distance between the button and the fixed plate. The prefabricated mix is pre-worn between the button and the fixed plate, and the lead pulls the distance between the fixed plate and the button after tightening and fixing. Prefabricated mix, make mix tight and knot. Finish the preliminary work of fixing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-absorbable Suture Anchor
Description: A conventional device used in surgery for shoulder dislocation.
Study: NCT02151552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)
Description: The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
Study: NCT00585117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET imaging with CuATSM
Description: Imaging with CuATSM